H.C. Wainwright raised the firm’s price target on Deciphera to $30 from $25 and keeps a Buy rating on the shares. The analyst says vimseltinib distinguished itself from competitors by “hitting across all marks.” The firm increased its probability of success of vimseltinib for tenosynovial giant cell tumor to 85%, up from 60%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DCPH:
- Deciphera upgraded to Buy from Hold at JonesResearch
- Piper upgrades Deciphera, sees vimseltinib and Qinlock poised for upside
- Deciphera upgraded to Overweight from Neutral at Piper Sandler
- Deciphera: MOTION study of vimseltinib met primary endpoint, key 2ndry endpoints
- Deciphera reports Q3 EPS (58c), consensus (61c)
